Literature DB >> 23552424

Evidence in support of RNA-mediated inhibition of phosphatidylserine-dependent HIV-1 Gag membrane binding in cells.

Vineela Chukkapalli1, Jingga Inlora, Gabrielle C Todd, Akira Ono.   

Abstract

The matrix domain promotes plasma-membrane-specific binding of HIV-1 Gag through interaction with an acidic lipid phosphatidylinositol-(4,5)-bisphosphate. In in vitro systems, matrix-bound RNA suppresses Gag interactions with phosphatidylserine, an acidic lipid prevalent in various cytoplasmic membranes, thereby enhancing the lipid specificity of the matrix domain. Here we provide in vitro and cell-based evidence supporting the idea that this RNA-mediated suppression occurs in cells and hence is a physiologically relevant mechanism that prevents Gag from binding promiscuously to phosphatidylserine-containing membranes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23552424      PMCID: PMC3676091          DOI: 10.1128/JVI.00075-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly.

Authors:  David E Ott; Lori V Coren; Tracy D Gagliardi
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Interactions of HIV-1 Gag with assembly cofactors.

Authors:  Nick Shkriabai; Siddhartha A K Datta; Zhuojun Zhao; Sonja Hess; Alan Rein; Mamuka Kvaratskhelia
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

3.  Immunoprecipitation of mRNA-protein complexes.

Authors:  Tiina Peritz; Fanyi Zeng; Theresa J Kannanayakal; Kalle Kilk; Emelía Eiríksdóttir; Ulo Langel; James Eberwine
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 4.  RNA polymerases I and III, growth control and cancer.

Authors:  Robert J White
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

5.  Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly.

Authors:  Jamil S Saad; Jaime Miller; Janet Tai; Andrew Kim; Ruba H Ghanam; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-13       Impact factor: 11.205

6.  Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras: implications for retrovirus assembly.

Authors:  Rachael M Crist; Siddhartha A K Datta; Andrew G Stephen; Ferri Soheilian; Jane Mirro; Robert J Fisher; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient gag membrane binding.

Authors:  Vineela Chukkapalli; Ian B Hogue; Vitaly Boyko; Wei-Shau Hu; Akira Ono
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides.

Authors:  Robin Chan; Pradeep D Uchil; Jing Jin; Guanghou Shui; David E Ott; Walther Mothes; Markus R Wenk
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

9.  Ubiquitination of human immunodeficiency virus type 1 Gag is highly dependent on Gag membrane association.

Authors:  Stefanie Jäger; Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

10.  HIV-1 matrix protein repositioning in nucleocapsid region fails to confer virus-like particle assembly.

Authors:  Ching-Yuan Chang; Yu-Fen Chang; Shiu-Mei Wang; Ying-Tzu Tseng; Kuo-Jung Huang; Chin-Tien Wang
Journal:  Virology       Date:  2008-06-12       Impact factor: 3.616

View more
  52 in total

1.  Effect of multimerization on membrane association of Rous sarcoma virus and HIV-1 matrix domain proteins.

Authors:  Robert A Dick; Elena Kamynina; Volker M Vogt
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  Basic motifs target PSGL-1, CD43, and CD44 to plasma membrane sites where HIV-1 assembles.

Authors:  Jonathan R Grover; Sarah L Veatch; Akira Ono
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 3.  Role of host tRNAs and aminoacyl-tRNA synthetases in retroviral replication.

Authors:  Danni Jin; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

4.  Phosphatidylinositol-(4,5)-Bisphosphate Acyl Chains Differentiate Membrane Binding of HIV-1 Gag from That of the Phospholipase Cδ1 Pleckstrin Homology Domain.

Authors:  Balaji Olety; Sarah L Veatch; Akira Ono
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  TIM-family proteins inhibit HIV-1 release.

Authors:  Minghua Li; Sherimay D Ablan; Chunhui Miao; Yi-Min Zheng; Matthew S Fuller; Paul D Rennert; Wendy Maury; Marc C Johnson; Eric O Freed; Shan-Lu Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  A conformational transition observed in single HIV-1 Gag molecules during in vitro assembly of virus-like particles.

Authors:  James B Munro; Abhinav Nath; Michael Färber; Siddhartha A K Datta; Alan Rein; Elizabeth Rhoades; Walther Mothes
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

7.  Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions.

Authors:  Ayna Alfadhli; August O Staubus; Philip R Tedbury; Mariia Novikova; Eric O Freed; Eric Barklis
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

8.  Molecular Determinants Directing HIV-1 Gag Assembly to Virus-Containing Compartments in Primary Macrophages.

Authors:  Jingga Inlora; Vineela Chukkapalli; Sukhmani Bedi; Akira Ono
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 9.  Roles played by acidic lipids in HIV-1 Gag membrane binding.

Authors:  Balaji Olety; Akira Ono
Journal:  Virus Res       Date:  2014-07-03       Impact factor: 3.303

Review 10.  HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.

Authors:  Paul Spearman
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.